In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.
about
Imaging of anticancer drug action in single cells.Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode.Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.BRAF inhibitors: resistance and the promise of combination treatments for melanoma.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.Excellent response to chemotherapy post immunotherapy.Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.Trial watch: Immune checkpoint blockers for cancer therapy.Immunoengineering with biomaterials for enhanced cancer immunotherapy.Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression.Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy.Mechanisms of resistance to immune checkpoint inhibitors.Immunotherapy in head and neck cancer: evidence and perspectives.Fc-mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers.Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.Anti-CTLA-4 therapy requires an Fc domain for efficacy.Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma.Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment.Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints.Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors.Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistanceTLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapyTurn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
P2860
Q39392711-09769A34-26DE-4D31-9AB9-57DCC900B579Q41514200-9E67EFD1-48FC-4872-B9C8-B7EDAD8D47A4Q41673094-484F8548-6703-4689-B199-5C80DF1758E0Q47104481-EC8019D7-372A-4815-9D6A-01B56EDDD910Q47120629-6EEADBC9-4699-4D90-A404-3BB938BFD585Q47132997-279BCCEC-5046-4794-80E9-4B994EBF454BQ47259728-AE659529-D984-4B21-84C7-E30227F80E7CQ47304240-DB8ABE95-1425-4FD6-9ED1-AB400FCCED31Q47393365-616D541F-0250-4379-B816-4C368F794750Q47732542-BD7CCD04-E139-4A85-8DFC-6EAF53711408Q47962563-5D2361A9-609D-428F-8F75-9BA26017EBFEQ48539402-3286EF74-C13F-42DC-9C91-1A6CC1987F00Q48638999-48F907DC-558A-44D4-9E42-8E3BF11F72F4Q49537326-B63AD8F4-2E31-4089-9D9C-D74645FF19AFQ49557927-27AEACC4-9938-4B19-B06E-127F7C60CB18Q49832498-F634CFA1-40B2-43EB-A1B3-DA2C4511F98EQ49859661-9A1F9478-BA4A-4BF7-BD54-B5BB84CF04EEQ52597541-A3BCC38C-ECE1-4698-8C5B-EC5AF1565861Q52629626-E8945204-4FFC-471C-9C97-71A090DCECF2Q52668254-2311BDDF-203A-4D7D-B304-615E730233A6Q53697047-2691C15E-6B87-4017-B715-9C0C4090A430Q54218762-A335374E-DE86-465F-A023-9E1A4B589B7EQ54960920-18128C49-3564-489A-AF15-2B859B126C69Q55019711-88E3160D-5AE1-42DA-AA20-D38CC28C67E7Q55262681-76048341-CD5C-46A9-9649-6153B6CE23B8Q55417775-73C42AA1-805B-4193-9807-B70B97420085Q57167969-3B6EC928-BA02-41FB-9CEA-22651DF8EB44Q57826568-1BACBC20-884F-4BD6-91C9-F708908D99B6Q58780996-04AB68D0-1AD6-4E2B-B552-6B8544C78B3F
P2860
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
In vivo imaging reveals a tumo ...... pathway in anti-PD-1 therapy.
@en
type
label
In vivo imaging reveals a tumo ...... pathway in anti-PD-1 therapy.
@en
prefLabel
In vivo imaging reveals a tumo ...... pathway in anti-PD-1 therapy.
@en
P2860
P50
P1476
In vivo imaging reveals a tumo ...... pathway in anti-PD-1 therapy.
@en
P2093
Maya Kitaoka
Robert M Anthony
P2860
P356
10.1126/SCITRANSLMED.AAL3604
P407
P50
P577
2017-05-01T00:00:00Z